Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
February 03, 2025 08:30 ET
|
Tenaya Therapeutics, Inc.
Funding will Support Ongoing RIDGE™-1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Initial Data from...
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
January 13, 2025 09:16 ET
|
Tenaya Therapeutics, Inc.
Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of...
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
December 17, 2024 07:00 ET
|
Tenaya Therapeutics, Inc.
TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA Expression and an Increase in Protein Levels...
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
December 16, 2024 16:30 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
November 25, 2024 08:30 ET
|
Tenaya Therapeutics, Inc.
TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address Underlying Disease RIDGE-1 Currently Enrolling at Six Centers;...
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 19, 2024 08:00 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024 16:05 ET
|
Tenaya Therapeutics, Inc.
Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 Trial of TN-201 Gene Therapy Initial TN-201 Data from Cohort 1 of MyPEAK-1...
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
October 17, 2024 16:30 ET
|
Tenaya Therapeutics, Inc.
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data from Cohort 1 to be Reported in December 2024...
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
September 03, 2024 08:30 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 16:05 ET
|
Tenaya Therapeutics, Inc.
Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing of...